Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

The Catalyst® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndromeWESTBROOK, Maine, June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. ID ...